Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Christian Rothermundt, MD, Kantonsspital St Gallen
Videos
Enzalutamide Plus Metformin Conveyed No Benefit for Disease Control Rate of Patients With Metastatic Castration-Resistant Prostate Cancer
10/12/2022
Dr Christian Rothermundt reviews the results of a phase 2 trial presented at the 2022 ESMO Congress, which demonstrated that adding metformin to enzalutamide conveyed no benefit for disease control rate of patients with metastatic...
Dr Christian Rothermundt reviews the results of a phase 2 trial presented at the 2022 ESMO Congress, which demonstrated that adding metformin to enzalutamide conveyed no benefit for disease control rate of patients with metastatic...
Dr Christian Rothermundt reviews...
10/12/2022
Oncology
Mark Robson, MD
Videos
BRCA Testing in the Era of PARP Inhibitors for Patients With Breast Cancer
10/12/2022
Mark Robson, MD, discusses BRCA testing and PARP inhibitors, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
Mark Robson, MD, discusses BRCA testing and PARP inhibitors, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
Mark Robson, MD, discusses BRCA...
10/12/2022
Oncology
Josep Tabernero, MD
Videos
Encorafenib-Centuximab Plus Chemotherapy Tolerable for BRAFV600E Metastatic Colorectal Cancer: BREAKWATER Trial
10/05/2022
Josep Tabernero, MD, reviews updated safety data from an analysis of the phase 3 BREAKWATER trial, evaluating encorafenib plus cetuximab plus chemotherapy for BRAFV600E metastatic colorectal cancer, as presented at the 2022 ESMO Congress.
Josep Tabernero, MD, reviews updated safety data from an analysis of the phase 3 BREAKWATER trial, evaluating encorafenib plus cetuximab plus chemotherapy for BRAFV600E metastatic colorectal cancer, as presented at the 2022 ESMO Congress.
Josep Tabernero, MD, reviews...
10/05/2022
Oncology
Videos
Cemiplimab for Advanced Basal Cell Carcinoma Ineligible for Surgery or Radiation
10/05/2022
Soo Park, MD, discusses cemiplimab for patients with advanced basal cell carcinoma that are ineligible for additional surgery or radiation and who cannot tolerate or have progressed on a hedgehog inhibitor.
Soo Park, MD, discusses cemiplimab for patients with advanced basal cell carcinoma that are ineligible for additional surgery or radiation and who cannot tolerate or have progressed on a hedgehog inhibitor.
Soo Park, MD, discusses...
10/05/2022
Oncology
Arvind Dasari, MD, MD Anderson Cancer Center
Videos
Fruquintinib Improves Survival for Patients With Heavily Pretreated Metastatic Colorectal Cancer
09/29/2022
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Arvind Dasari, MD, discusses...
09/29/2022
Oncology
Joseph Chao, MD, City of Hope Comprehensive Cancer Center
Videos
New and Targeted Therapy for Gastric Cancer: A Focus on Immunotherapy and HER2
09/29/2022
Joseph Chao, MD, reviews his presentation on new and upcoming targeted agents in gastric cancer from the Great Debates and Updates in Gastrointestinal Malignancies virtual meeting in September 2022.
Joseph Chao, MD, reviews his presentation on new and upcoming targeted agents in gastric cancer from the Great Debates and Updates in Gastrointestinal Malignancies virtual meeting in September 2022.
Joseph Chao, MD, reviews his...
09/29/2022
Oncology
Simon Crabb, PhD, MBBS, University of Southampton
Videos
Maintenance Rucaparib Following Chemotherapy for DNA Repair Deficiency Biomarker-Positive Urothelial Carcinoma
09/29/2022
Simon Crabb, PhD, MBBS, reviews results from a randomized, double-blind phase 2 trial of maintenance rucaparib following chemotherapy in DNA repair deficiency biomarker-positive patients with metastatic urothelial carcinoma.
Simon Crabb, PhD, MBBS, reviews results from a randomized, double-blind phase 2 trial of maintenance rucaparib following chemotherapy in DNA repair deficiency biomarker-positive patients with metastatic urothelial carcinoma.
Simon Crabb, PhD, MBBS, reviews...
09/29/2022
Oncology
Evan Yu, MD, Fred Hutchinson Cancer Center
Videos
Pembrolizumab Plus Olaparib Conveyed No Survival Benefit in Metastatic Castration-Resistant Prostate Cancer
09/29/2022
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
Evan Yu, MD, reviews the results...
09/29/2022
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement